{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T21:23:09Z","timestamp":1788988989957,"version":"build-2803163510"},"reference-count":20,"publisher":"Japanese Society of Internal Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,2,15]]},"DOI":"10.2169\/internalmedicine.3782-19","type":"journal-article","created":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T22:04:13Z","timestamp":1572473053000},"page":"569-572","source":"Crossref","is-referenced-by-count":10,"title":["Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus"],"prefix":"10.2169","volume":"59","author":[{"given":"Misato","family":"Jono","sequence":"first","affiliation":[{"name":"Department of Medicine, Nippon Life Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhei","family":"Kinehara","sequence":"additional","affiliation":[{"name":"Department of Medicine, Nippon Life Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Utsu","sequence":"additional","affiliation":[{"name":"Department of Medicine, Nippon Life Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiro","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Medicine, Nippon Life Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Koseto","sequence":"additional","affiliation":[{"name":"Department of Medicine, Nippon Life Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruaki","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Medicine, Nippon Life Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akifumi","family":"Uota","sequence":"additional","affiliation":[{"name":"Department of Medicine, Nippon Life Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusuke","family":"Ninomiya","sequence":"additional","affiliation":[{"name":"Department of Medicine, Nippon Life Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Komo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Nippon Life Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Sumitani","sequence":"additional","affiliation":[{"name":"Department of Medicine, Nippon Life Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bunzo","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Medicine, Nippon Life Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soji","family":"Kasayama","sequence":"additional","affiliation":[{"name":"Department of Medicine, Nippon Life Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Tachibana","sequence":"additional","affiliation":[{"name":"Department of Medicine, Nippon Life Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373: 1627-1639, 2015.","DOI":"10.1056\/NEJMoa1507643"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375: 1823-1833, 2016.","DOI":"10.1056\/NEJMoa1606774"},{"key":"3","unstructured":"3. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389: 255-265, 2017."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378: 2078-2092, 2018.","DOI":"10.1056\/NEJMoa1801005"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 379: 2040-2051, 2018.","DOI":"10.1056\/NEJMoa1810865"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378: 2288-2301, 2018.","DOI":"10.1056\/NEJMoa1716948"},{"key":"7","unstructured":"7. Ricciuti B, Baglivo S, Paglialunga L, et al. Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy. Ther Adv Med Oncol 9: 387-404, 2017."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Leonardi GC, Gainor JF, Altan M, et al. Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders. J Clin Oncol 36: 1905-1912, 2018.","DOI":"10.1200\/JCO.2017.77.0305"},{"key":"9","unstructured":"9. Richter MD, Pinkston O, Kottschade LA, Finnes HD, Markovic SN, Thanarajasingam U. Brief report: cancer immunotherapy in patients with preexisting rheumatic disease: the Mayo Clinic experience. Arthritis Rheumatol 70: 356-360, 2018."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Castellino G, Govoni M, Giacuzzo S, Trotta F. Optimizing clinical monitoring of central nervous system involvement in SLE. Autoimmun Rev 7: 297-304, 2008.","DOI":"10.1016\/j.autrev.2007.11.022"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Sato S, Yashiro M, Asano T, Kobayashi H, Watanabe H, Migita K. Association of anti-triosephosphate isomerase antibodies with aseptic meningitis in patients with neuropsychiatric systemic lupus erythematosus. Clin Rheumatol 36: 1655-1659, 2017.","DOI":"10.1007\/s10067-017-3653-2"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kimura A, Kanoh Y, Sakurai T, et al. Antibodies in patients with neuropsychiatric systemic lupus erythematosus. Neurology 74: 1372-1379, 2010.","DOI":"10.1212\/WNL.0b013e3181dad590"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40: 1725, 1997.","DOI":"10.1002\/art.1780400928"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kassan SS, Lockshin MD. Central nervous system lupus erythematosus. The need for classification. Arthritis Rheum 22: 1382-1385, 1979.","DOI":"10.1002\/art.1780221210"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Okamoto H, Kobayashi A, Yamanaka H. Cytokines and chemokines in neuropsychiatric syndromes of systemic lupus erythematosus. J Biomed Biotechnol 2010: 268436, 2010.","DOI":"10.1155\/2010\/268436"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Hirohata S, Kanai Y, Mitsuo A, Tokano Y, Hashimoto H. Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis. A multicenter retrospective study. Clin Rheumatol 28: 1319-1323, 2009.","DOI":"10.1007\/s10067-009-1226-8"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Martin-Liberal J, Kordbacheh T, Larkin J. Safety of pembrolizumab for the treatment of melanoma. Expert Opin Drug Saf 14: 957-964, 2015.","DOI":"10.1517\/14740338.2015.1021774"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Salam S, Lavin T, Turan A. Limbic encephalitis following immunotherapy against metastatic malignant melanoma. BMJ Case Rep 2016: bcr2016215012, 2016.","DOI":"10.1136\/bcr-2016-215012"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Chipman RG, Aparna H, Cynthia C, et al. Tocilizumab for the management of immune mediated adverse events secondry to PD-1 blockade. J Oncol Pharm Practice 25: 551-557, 2019.","DOI":"10.1177\/1078155217745144"},{"key":"20","unstructured":"20. Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review. Ann Intern Med 168: 121-130, 2018."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/4\/59_3782-19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,15]],"date-time":"2020-02-15T03:39:50Z","timestamp":1581737990000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/4\/59_3782-19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,15]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3782-19","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,15]]}}}